NUFS‐sErt and NUFS technology may thus serve as new treatment strategies in EGFR‐mutant lung cancer patients with CNS failure and help to resolve some of the drug delivery issues with conventional EGFR‐TKIs. This evidence concerns the gene EGFR and lung carcinoma.